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Abstract (250 words) 53 
Parathyroid tumors display reduced sensitivity to extracellular calcium ([Ca
2+
]o). [Ca
2+
]o 54 
activates calcium-sensing receptor (CASR), which interacts with the scaffold protein filamin A 55 
(FLNA). The study aimed to investigate: 1) the FLNA expression in human parathyroid tumors, 2) 56 
its effects on the CASR mRNA and protein expression, and 3) on ERK signaling activation, 4) the 57 
effect of the carboxy-terminal CASR variants and 5) of the treatment with the CASR agonist R568 58 
on FLNA-mediated ERK phosphorylation in HEK293 cells. 59 
Full-length FLNA immunostaining was variably reduced in parathyroid tumors. 60 
Immunofluorescence showed that FLNA localized in membrane and cytoplasm and co-localized 61 
with CASR in parathyroid adenomas (PAds)-derived cells. Cleaved C-terminus FLNA fragment 62 
could also be detected in PAds nuclear protein fractions. In HEK293 cells transfected with 990R-63 
CASR or 990G-CASR variants, silencing of endogenous FLNA reduced CASR mRNA levels and 64 
total and membrane-associated CASR proteins. In agreement, FLNA mRNA levels positively 65 
correlated with CASR expression in a series of 74 PAds; however, any significant correlation with 66 
primary hyperparathyroidism severity could be detected and FLNA transcript levels did not differ 67 
between PAds harboring 990R or 990G CASR variants. R568 treatment was efficient in restoring 68 
990R-CASR and 990G-CASR sensitivity to [Ca
2+
]o in absence of FLNA. 69 
In conclusion, FLNA is down-regulated in parathyroid tumors and parallels the CASR 70 
expression levels. Loss of FLNA reduces CASR mRNA and protein expression levels and the 71 
CASR-induced ERK phosphorylation. FLNA is involved in receptor expression, membrane 72 
localization and ERK signaling activation of both 990R and 990G CASR variants.  73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
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Introduction 83 
Tumors of the parathyroid glands display reduced sensitivity to extracellular calcium 84 
([Ca
2+
]o) resulting in failure in inhibiting parathormone (PTH) synthesis and release. Overall, 85 
derangements in calcium sensing result in increased parathyroid cell proliferation. The parathyroid 86 
cell sensitivity to [Ca
2+
]o is mediated by the calcium-sensing receptor (CASR). CASR is a G-protein 87 
coupled membrane receptor interacting with different intracellular pathways (Breitwieser 2013; 88 
Conigrave & Ward 2013): active CASR dimers increase inositol-triphosphate and intracellular 89 
calcium concentrations, activate protein kinase C and intracellular calcium oscillations, and 90 
stimulate mitogen activated protein kinase (MAPK) cascade through p44/42 extracellular signaling-91 
regulated kinase (ERK) phosphorylation (Breitwieser & Gama 2001; Corbetta et al. 2002; 92 
Chakravarti et al. 2012). CASR activates intracellular signaling through direct interaction with 93 
Gq/11 protein and the cytoskeletal scaffold protein filamin A (Awata et al. 2001; Hjalm et al. 94 
2001).  95 
Parathyroid tumors are characterized by variable degrees of insensitivity to [Ca
2+
]o, 96 
sustained by deregulation of key molecular components of CASR-coupled intracellular signaling: 97 
CASR mRNA and protein expression is down-regulated (Corbetta et al. 2000; Varshney et al. 98 
2013a); the major 990R allele of the CASR gene is associated with higher serum PTH levels 99 
(Corbetta et al. 2006) in hyperparathyroid patients and with in vitro lower responsiveness to [Ca
2+
]o 100 
than the minor CASR 990G allele (Terranegra et al. 2010); Gq/11 protein expression is reduced 101 
(Corbetta et al. 2000); CASR-stimulated p44/42 ERK activity is blunted (Corbetta et al. 2002). 102 
Filamin A (FLNA) is a 280 kDa protein that contains N-terminal actin-binding domain and 103 
consists of 24 repeated domains of approximately 96 amino acids each. FLNA is a scaffolding 104 
molecule facilitating protein interaction. The C-terminal domains 14 and 15 of FLNA interact with 105 
the carboxyl-terminal portion of CASR (Awata et al. 2001; Hjalm et al. 2001). This interaction 106 
stabilizes CASR in membrane and reduces its degradation, thereby facilitating the MAPK signaling 107 
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(Zhang & Breitwieser 2005). In adult cells, FLNA regulates cell cycle: suppression of FLNA leads 108 
to prolongation of the cell cycle, mainly in the M phase, and increases phosphorylation of cyclin-109 
dependent kinase 1 (Lian et al. 2012). Moreover, FLNA plays a significant role in cancer 110 
development and progression: a number of human cancers overexpress FLNA. By contrast, in 111 
human prolactin-secreting pituitary adenomas resistant to dopamine treatment, a tumor model close 112 
to human parathyroid tumors, FLNA expression is diminished and involved in dopamine resistance 113 
(Peverelli et al. 2012). 114 
Data about FLNA in parathyroid cells are from neonatal bovine parathyroid glands, whose 115 
dispersed cells express endogenously FLNA at confocal immunofluorescence microscopy: FLNA 116 
exhibits the highest density within the cytoplasm  and colocalizes with endogenous CASR proteins 117 
(Hjalm et al. 2001). To our knowledge, data about FLNA expression in human parathyroid cells 118 
from normal or tumor glands are still lacking. 119 
In the present study, we investigated: 1) the FLNA expression in parathyroid adenomas and 120 
carcinomas samples compared to normal glands from normocalcemic subjects; 2) the effects of 121 
FLNA loss on CASR expression, 3) on CASR-activated ERK signaling and 4) in presence of the 122 
CASR agonist R568 in HEK293 cells transiently transfected with CASR; 5) whether the 990G-123 
CASR variant expression and function were differently affected by FLNA loss with respect to the 124 
990R variant. 125 
 126 
Methods 127 
Sample collection 128 
Formalin-fixed paraffin-embedded sections from 4 normal parathyroid glands incidentally 129 
removed during thyroid surgery of normocalcemic patients, 17 parathyroid tumors (10 typical 130 
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parathyroid adenomas and 7 parathyroid carcinomas) from patients with primary 131 
hyperparathyroidism (PHPT) were collected and analyzed by immunohistochemistry. Fresh tissue 132 
samples from 3 parathyroid adenomas (PAds) were collected, fragmented and the dispersed cells 133 
were cultured for immunofluorescence experiments.  134 
Immunohistochemistry (IHC) 135 
Archival parathyroid normal and tumor samples (6 normal parathyroid glands incidentally 136 
removed from normocalcemic patients during surgery for thyroid diseases, 10 sporadic benign 137 
PAds and 7 parathyroid carcinomas (PCas) from patients with PHPT were used for 138 
immunhistochemistry after tissues morphology was assessed by haematoxylin and eosin staining. 139 
Histological diagnosis of parathyroid carcinoma was established according to WHO published 140 
guidelines (Bondeson et al. 2004). Briefly, IHC was performed using an anti-human full-length 141 
FLNA antibody (1:200; Abnova Corporation, Taipei City, Taiwan) as previously described 142 
(Peverelli et al. 2012). Slides with absence of the primary antibody were included as negative 143 
controls. Percentage of positive cells was calculated considering at least 400 cells in the main 144 
representative high-power field, as previously described (Lania et al. 2004); blinded scoring of the 145 
cells was performed by an experienced pathologist (S.F.). 146 
Immunofluorescence (IF)  147 
Human PAds-derived cells (n=3) cultured for 48 hours, and subconfluent HEK293 cells 148 
were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, and blocked in 1% BSA-149 
PBS for 2 hours. Then, cells were incubated with primary antibodies against human full length 150 
FLNA (mouse monoclonal H00002316-M01; Abnova Corp., Taipei, Taiwan) and human CASR 151 
(rabbit polyclonal PA1-934; Affinity Bioreagents, Golden, CO, USA), overnight at 4°C, washed 152 
thrice in PBS and followed by incubation with secondary antibodies conjugated with FITC or 153 
DyLight549 (1:100; Jackson Immuno Research, Milan, Italy). Nuclei were stained with Hoechst 154 
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33342 (1:500 dilution). For negative controls, PBS was used instead of primary antibodies to 155 
exclude unspecific binding of secondary antibody. Images were captured using a fluorescent 156 
confocal microscope (TCS SP2, Leica, Milan, Italy) and a digital camera. 157 
Nuclear cleaved FLNA fragment expression in parathyroid tissues 158 
Cells were homogenized using a Nuclear Extract kit (Active Motif, Carlsbad CA USA) 159 
following the manufacturer’s instructions in order to obtain both citoplasmic and nuclear protein 160 
fractions. The kit provide protease and phosphatase inhibitors cocktail for the cell lysis and protein 161 
extraction procedures. Samples (40 µg proteins) were denatured with loading dye and β-162 
mercaptoethanol for 10 min at 95°C. Proteins were separated on 10% w/v SDS-PAGE and antigen 163 
were revealed by a primary antibody that recognized the C-terminal (90-100kDa) calpain cleavage 164 
fragment of Filamin A (Millipore, Darmstadt, Germany). Histone H3 was used as internal control 165 
(Abcam, Cambridge, UK). Specific protein bands were detected using SuperSignal West Pico 166 
enhanced chemiluminescence system (Pierce, Rockford, IL, USA). 167 
Quantitative Real-Time PCR 168 
Total RNA was extracted from frozen human PAds samples using Trizol Reagent 169 
(ThermoFischer Scientific) following manufacturer’s instructions. One microg of RNA was 170 
digested with DNAse I (ThermoFischer Scientific) to remove genomic DNA contamination and 171 
reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad, Segrate, Milan, Italy). CASR 172 
and FLNA expression levels were estimated by quantitative real-time PCR using specific primers: 173 
CASR gene (Forward: 5’-ATGCCAAGAAGGGAGAAAGACTCTT-3’; Reverse: 5’-174 
TCAGGACACTCCACACACTCAAAG-3’); FLNA gene (Forward: 5’-175 
CAGTGCTATGGGCCTGGTAT-3’; Reverse: 5-’CCACTTTGTACATGCCATCG-3’); 176 
housekeeping GAPDH gene (Forward: 5’-CTCATGA-CCACAGTCCATGCCATC-3’ and Reverse: 177 
5’-CATGCCAGTGAGCTTCCCGTT-3’). Real-time PCR was performed with 7500 Fast Real-178 
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Time PCR Systems (Applied Biosystems, Life Technologies) with 100 ng of cDNA as template and 179 
SYBR Premix Ex TaqTM II (Takara Bio Inc, Japan). Specific temperature of primers annealing 180 
were 57°C for CASR gene, 65°C for FLNA gene or 60°C for GAPDH. Mean cycle threshold values 181 
of triplicate samples were used for analysis. Data were analyzed by 7500 Fast System SDS 182 
Software. CASR and FLNA mRNA quantities were normalized using the housekeeping GAPDH 183 
expression levels and data were expressed as CASR/GAPDH and FLNA/GAPDH mRNA ratios. 184 
Culture of parathyroid adenomas (PAds)-derived and Human Embryonic Kidney (HEK293) cells 185 
Samples from human parathyroid adenomas (PAds) were cut into fragments less than 1 186 
mm
3
, washed with PBS and partially digested with 2 mg/ml collagenase type I (Worthington, 187 
Lakewood, NJ, USA). After digestion, tissues fragments were filtered with a cell strainer (100 µm 188 
Nylon, BD Falcon, Milan, Italy). Cells derived from human PAds and Human Embryonic Kidney 189 
(HEK293) cells were routinely grown in DMEM medium, supplemented with 10% FBS, 2 mM L-190 
glutamine and 1% penicillin/streptomycin (all from Gibco-Invitrogen, ThermoFischer Scientific, 191 
Wlatham, MA, USA) under standard culture conditions (5% CO2, 37°C).  192 
CASR gene transfection and FLNA silencing 193 
HEK293 cells were plated in MW6 plates at a density of 10
5 
cells/well in complete medium. 194 
When cells reached 70-90% confluence, they were simultaneously silenced for FLNA, with 195 
predesigned small interfering RNA (siRNA) (Stealth RNAi HSS103734, Invitrogen), and 196 
transiently transfected with plasmid encoding for wild-type CASR (990R-CASR), obtained by site-197 
directed mutagenesis as previously described (Terranegra et al. 2010) or 990G-CASR, kindly 198 
provided by Dr Jianxin Hu (NIH, Bethesda, MD, USA). Transfection, silencing and co-transfection 199 
was performed with 10, 5 and 12 µl Lipofectamine 2000 (Invitrogen) respectively, 4 µg CASR 200 
plasmid and 500 pmol of FLNA siRNA in OptiMEM serum-free medium (Invitrogen) for each 201 
well. To obtain the best efficiency of FLNA silencing, three different human FLNA siRNA were 202 
tested. Preliminary experiments to determine the optimal concentration of siRNA and the FLNA 203 
Page 8 of 39
  
 
Mingione et al. 9
silencing kinetics were performed. As negative control in each experiment, medium GC duplex 204 
stealth RNAi negative control duplex human (control-siRNA) was used as indicated by manufacture 205 
instructions (Invitrogen). The growth medium was changed to starvation medium (serum-free 206 
medium supplemented with 0.2% BSA and 1% penicillin/streptomycin) 24 hours after co-207 
transfection. Gene expression and activity were tested 72 hours after transfection.  208 
Total and membrane CASR and FLNA proteins quantifications 209 
HEK293 cells, plated in MW6 plates, were trypsinized and the pellets were lysed with ice-210 
cold lysis buffer (150 mM NaCl, 10 mM TRIS-HCl pH 7.2, 0.1% SDS, 1% Triton X-100, 1% 211 
deoxycholate, 5 mM EDTA, 1 mM PMSF, 10 mM benzamidine, 2µg/ml leupeptin, 0.1 mM Na-212 
Orthovanadate). The lysates were centrifuged and the surnatants were recollected to quantify 213 
proteins by BCA protein assay kit (Pierce). The membrane proteins extraction was performed with 214 
Mem-Per plus Kit by manufacture instructions (ThermoFischer Scientific, Life Technologies Italia, 215 
Monza, MB, Italy). All samples (10 µg proteins/well) were denatured with loading dye buffer and 216 
β-mercaptoethanol for 10 min at 95°C to obtain proteins for FLNA and ERK analysis, or with 217 
denaturing buffer: 7M Urea, 2 M Thiourea, 65 mM DTT, 5x Laemmli sample buffer (final 218 
concentration 2% SDS) for 30 min at room temperature for the analysis of the CASR dimeric (250 219 
kDa) and monomeric (130-150 kDa) receptor isoforms. Iodoacetamide (130 mM) was added to 220 
block DTT for 30 min at room temperature. Proteins were separated by 8% w/v SDS-PAGE, then 221 
electrotransferred to PVDF membrane. The blots were blocked in a blocking solution (5% milk in 222 
TBST or 5% BSA in TBST) and then incubated overnight at 4°C with different antibodies: 1:5000 223 
dilution monoclonal CASR antibody (Affinity Bioreagents, Golden, CO, USA), 1:10000 dilution 224 
monoclonal anti-GAPDH antibody (Abnova Corporation, Taipei, Taiwan), 1:1000 dilution 225 
polyclonal anti-β-actin antibody (Sigma Chemicals, St Louis, MO, USA) and 1:1000 dilution anti-226 
Na/K-ATPase antibody (Cell Signaling, Danvers, MA, USA), for 2 hours at room temperature. The 227 
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FLNA expression levels were assessed in each experiment with 1:5000 dilution monoclonal full-228 
length FLNA antibody (Abnova Corporation). Membranes were incubated in the blocking solution 229 
with secondary horseradish peroxidase-coupled anti-mouse or anti-rabbit IgG (Jackson 230 
ImmunoResearch Laboratories, Suffolk, UK). Specific protein bands were detected using 231 
SuperSignal West Pico enhanced chemiluminescence system (Pierce, Rockford, IL, USA). 232 
Experiments were repeated at least thrice. The band intensities, corresponding to the levels of 233 
protein expression, were measured by Image J software.  234 
Phosphorylated ERK1/2 quantification 235 
Serum-starved transfected HEK293 cells were stimulated with increasing concentrations of calcium 236 
chloride (CaCl2; 0.5, 1.0, 3.0 and 5.0 mM) with or in absence of the calcimimetic R568 (0.01 µM; 237 
kindly provided by Amgen Inc., Thousand Oaks, CA, USA) for 10 min at 37°C in saline solution 238 
PSS (NaCl 125 mM, KCl 4 mM, HEPES 20 mM, D-Glucose 0.1%, NaH2PO4 0.8 mM, MgCl2 1 239 
mM, pH 7.45). Incubation was stopped by placing the cells on ice. The PSS was removed and cells 240 
were treated with 50 µl ice-cold lysis buffer as described above, supplemented with complete 241 
phosphatase inhibitor cocktail (Roche Diagnostics Spa, Monza, MB, Italy). Samples (20 µg 242 
proteins/well) were denatured with loading dye and β-mercaptoethanol for 10 min at 95°C. Proteins 243 
were separated on 10% w/v SDS-PAGE and analysis of ERK1/2 activation was performed by 244 
western blot with 1:1000 and 1:2000 dilution polyclonal anti-p44/42 ERK and anti-phospho-p44/42 245 
ERK antibodies, respectively (Cell Signaling Technology, Beverly, MA, USA). Specific protein 246 
bands were detected by a chemiluminescent method as described above for CASR and FLNA 247 
proteins quantification. Experiments were repeated at least thrice. 248 
Genotyping 249 
Genomic DNA was extracted from 74 frozen human PAds tissues samples using Trizol 250 
reagent (Invitrogen) following manufacture’s instructions. CASR R990G SNP genotyping was 251 
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performed by a specific Taqman® SNP genotyping assay (C_7504854_20, Life Technologies Ltd, 252 
Inchinnan, UK) with the Applied Biosystems® 7500 Fast Real-Time PCR Systems. Amplification 253 
was performed in 8 µl final volume with 20 ng of genomic DNA at the following conditions: 95°C 254 
for 20 sec, and 40 cycles each of 95°C for 3 sec and 60°C for 30 sec. SNP variation was assessed by 255 
means of the allelic discrimination assay employing the Applied Biosystems Software Package SDS 256 
2.1.  257 
PHPT patients 258 
We collected the clinical and biochemical data of the 74 patients with primary 259 
hyperparathyroidism (PHPT)(57 females, 17 males, age 59.7±14.2 years), whose surgically 260 
removed PAds were analyzed. PHPT was diagnosed when hypercalcemia (serum calcium>10.2 261 
mg/dL and/or ionized calcium>1.30 mmol/L) and elevated or inappropriately normal serum PTH 262 
level occurred. Exclusion criteria were diagnosis of familial hypocalciuric hypercalcemia [detection 263 
of calcium-to-creatinine clearance ratio > 0.01 following vitamin D deficiency correction (Marcocci 264 
et al. 2015)], previously established diagnosis of chronic kidney disease, hyperthyroidism, 265 
pregnancy, glucocorticoids, bisphosphonates, diuretics and calcimimetic treatments. All patients 266 
were Caucasians. Patients underwent clinical and laboratory evaluation, including: 1) personal and 267 
family medical history; 2) physical examination including arterial blood pressure, weight and height 268 
measurement; 3) fasting biochemical evaluation including total and ionized calcium, phosphate, 269 
intact PTH, 25hydroxyvitaminD3, creatinine; a 24 hours urine collection was obtained from all 270 
patients for urinary calcium and phosphate excretion; 4) imaging evaluation including lumbar and 271 
femoral dual-energy X-ray absorptiometry (DEXA), vertebral spine X-ray and ultrasound kidney 272 
examination. Osteoporosis was diagnosed in 50% and kidney stones in 30% of PHPT patients. 273 
Biochemical and hormonal parameters were assayed by routine methods. All participants gave their 274 
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informed consent after full explanation of the purpose and nature of all used procedures; the 275 
protocol study was approved by the local ethics committee.  276 
Statistical analysis 277 
Results are expressed as mean±standard error of the mean (SEM) or median and range 278 
interquartile. Analysis of variance was performed by ANOVA or Wilcoxon rank-sum tests. 279 
Correlation between FLNA and CASR expression levels in PAds was analyzed by linear regression 280 
analysis. Differences between two groups were tested by Student’s t-test or Mann Whitney test. A 281 
p-value < 0.05 was considered statistically significant.  282 
 283 
Results  284 
FLNA protein expression in human normal and tumor parathyroids 285 
In normal parathyroid glands (n=6), most epithelial parathyroid cells showed intense 286 
staining for full-length FLNA in the cytoplasm and at membrane level (Fig. 1, panel A, a). 287 
Endothelial cells lining the vessels showed intense staining for FLNA [arrows in Figure 1, panel A, 288 
a-c] and were considered as internal positive controls. A pattern of staining similar to that in normal 289 
parathyroid glands was detected in sporadic parathyroid adenomas samples (PAds, n=10), though 290 
the amount of FLNA-expressing cells was variably reduced among the samples (Fig. 1, panel A, b-291 
c) ranging from 50% to 10% of tumor parathyroid epithelial cells. Remarkably, the FLNA-292 
expressing cells were <10% or absent in parathyroid carcinomas (PCas, n=7) (Fig. 1, panel A, d). 293 
Therefore, a subset of PAds and the most PCas showed a variable loss of FLNA-expressing cells 294 
(Fig. 1, panel B). By immunofluorescence on PAds-derived cultured single cells, full-length FLNA 295 
was detected at membrane level and in the cytoplasm of a subset of tumor parathyroid cells, where 296 
it co-localized with CASR with a membrane and peripheral cytoplasmic distribution (Fig. 1, panel 297 
C). Indeed, immunoblotting fractioned proteins from HEK293 cells and PAds, using a primary 298 
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antibody against the C-terminal calpain cleaved fragment of FLNA, detected a specific band of 100 299 
kDa in the nuclear protein fractions. An additional band of 270 kDa corresponding to the full-length 300 
FLNA, was also visualized in all samples (Fig. 1, panel D); the nuclear accumulation of full-length 301 
FLNA, though detected by IHC in some tumor cells (data not shown), may be related to the 302 
sensitivity of the immunoblotting on fractioned proteins.  303 
Effect of FLNA gene silencing on CASR expression levels 304 
The effect of FLNA loss on CASR expression was investigated in 990R-CASR-transiently 305 
transfected HEK293 cells silenced for FLNA by siRNA technique. As shown in Fig. 2, panel A, in 306 
HEK293 cells, 72 hours-FLNA silencing consistently decreased endogenous FLNA protein 307 
expression (about 70-80%), compared to control siRNA transfected cells. The siRNA efficiency 308 
was not affected by cotransfection of the CASR plasmids (Fig. 2, panel A). 309 
Loss of FLNA significantly reduced the total and membrane 990R-CASR protein levels 310 
(Fig. 2, panels B and C). Cotransfection of the 990R-CASR plasmid and control siRNA did not 311 
affect the 990R-CASR expression levels both in the total and in the membrane protein fractions, 312 
which were similar to those detected in HEK293 cells transfected with the 990R-CASR plasmid 313 
alone (Fig. 2, panels B and C).  314 
FLNA and CASR mRNA expression levels in PAds  315 
Loss of FLNA-induced CASR protein reduction might be due to reduced receptor 316 
stabilization with consequent increased degradation and/or by inhibition of CASR gene expression. 317 
The FLNA full-length and cleaved fragments can regulate gene expression directly or indirectly 318 
through interaction with a number of intracellular pathways (Savoy & Ghosh 2013). We observed 319 
that FLNA silencing also reduced CASR mRNA levels in 990R-CASR-HEK293 cells (Fig. 3, panel 320 
A). HEK293 cells do not express endogenous CASR gene and protein and the 990R-CASR-HEK293 321 
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cell model was generated by transfecting a CASR plasmid lacking the endogenous regulatory 322 
region. Therefore, loss of FLNA-induced CASR inhibition could not be a direct nuclear effect. 323 
We further investigated FLNA and CASR mRNA expression levels in tissue samples from 324 
74 sporadic PAds surgically removed from patients with a clinical and hormonal diagnosis of 325 
PHPT. FLNA and CASR mRNA levels, reported as a ratio with GAPDH mRNA, were highly 326 
variable among PAds samples and CASR mRNA levels positively correlated with FLNA mRNA 327 
levels (r
2
=0.223 P<0.0001) (Fig. 3, panel B), suggesting a potential modulation of the CASR gene 328 
transcript by FLNA. Nonetheless, FLNA and CASR mRNA levels of PAds did not show any 329 
significant correlation with the PHPT severity (Table 1): FLNA and CASR mRNA levels of PAds 330 
associated with severe PHPT, defined as clinical diagnosis of kidney stones and/or osteoporosis 331 
and/or osteoporotic fractures and/or serum calcium > 1 mg/dl above the upper limit of the normal 332 
range, were similar to those detected in PAds associated with mild PHPT (Marcocci et al. 2015).  333 
However, CASR and FLNA protein expression levels, detected by western blot analysis, did 334 
not show significant correlation (Fig. 3A and 3B): though there were tumors (PAd1 and PAd6) with 335 
low FLNA levels and low CASR levels or high FLNA levels and high CASR levels (PAd2), other 336 
tumors (PAd 3 and PAd4) had low FLNA levels and consistent CASR expression levels or high 337 
FLNA levels and low CASR levels (PAd5).  338 
Effect of the 990G CASR allele on FLNA and CASR mRNA expression 339 
Genotyping for the CASR 990 single nucleotide variants of the PAds samples identified 68 340 
tumors harboring the major allele 990R and 6 tumors harboring the minor allele 990G of the CASR 341 
gene. PAds harboring the 990G CASR variant were associated with mean serum intact PTH levels 342 
lower than those in PAds harboring the 990R variant (171.0±24.9 vs 328.1±44.0 pg/ml, P=0.003), 343 
while mean serum albumin-corrected calcium levels were similar (11.3±0.4 vs 11.6±0.1 mg/dl; 344 
P=0.76). No significant difference could be detected in the PAds harboring the 990R compared with 345 
PAds harboring the 990G variants in the median expression levels of the FLNA (median, range 346 
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interquartile: 0.08, 0.04-0.15 vs 0.09, 0.06-0.31; P=0.33; Fig. 4, panel C) and CASR genes (median, 347 
range interquartile: 0.68, 0.43-0.96 vs 0.84, 0.56-2.98; P=0.14; Fig. 4, panel D).  348 
Effect of FLNA gene silencing on the CASR-stimulated p44/42 ERK phosphorylation  349 
To evaluate the effect of the loss of FLNA expression on the CASR-activated signaling, we 350 
measured the levels of phosphorylated p44/42 ERK in 990R-CASR cells after FLNA silencing. 351 
After 72 hours-incubation with FLNA siRNA or control siRNA, 990R-CASR was activated by 352 
increasing extracellular calcium concentrations ([Ca
2+
]o), from 0.5 to 1.0, 3.0, and 5.0 mM, as 353 
shown in Fig. 5, panel A. Loss of FLNA expression in 990R-CASR HEK293 cells did not 354 
significantly alter ERK phosphorylation levels at 0.5 and 1.0 mM [Ca
2+
]o, while at 3.0 and 5.0 mM 355 
[Ca
2+
]o it significantly decreased the 990R-CASR activation induced phospho-ERK levels 356 
compared to those detected in 990R-CASR HEK293 cells transfected with the control siRNA 357 
(0.75±0.06 vs 0.92±0.08; P=0.006 at 3.0 mM [Ca
2+
]o; 0.71±0.24 vs 1.21±0.38; P=0.02 at 5.0 mM 358 
[Ca
2+
]o)(Fig. 5, panel A). The incubation with the potent calcimimetic R568 0.01 µM blunted the 359 
effect of FLNA loss on the 990R-CASR-induced phosphorylation of ERK at any [Ca
2+
]o (Fig. 5, 360 
panel B).  361 
Effects of the 990G CASR allele on FLNA-modulated CASR protein expression and CASR-mediated 362 
ERK phosphorylation 363 
In HEK293 cells co-transfected with either 990R-CASR and 990G-CASR and siRNA 364 
control, we observed that the amount of 990G-CASR in the membrane protein fraction was 365 
significantly higher than that of 990R-CASR (5.3±0.25 vs 4.4±0.1, P=0.03) (Fig. 2, panel C). Loss 366 
of FLNA in 990G-CASR-HEK293 cells reduced the total and membrane 990G-CASR protein 367 
levels at an extent similar to that observed in the 990R-CASR transfected HEK293 cells (Fig. 2, 368 
panels B and C). In HEK293 cells transfected with the 990G-CASR and endogenous FLNA, 990G-369 
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CASR activation by increasing [Ca
2+
]o stimulated ERK phosphorylation at higher levels than that 370 
observed in 990R-CASR-expressing cells, which gained the statistical significance at 5.0 mM 371 
[Ca
2+
]o (2.80±0.68 vs 1.21±0.38; P=0.02), in agreement with previous report (Terranegra et al. 372 
2010)(Fig. 5, panel A). Loss of FLNA by treatment with siRNA reduced 990G-CASR-induced 373 
phospho-ERK levels with a significant difference at 5.0 mM [Ca
2+
]o (1.33±0.43 vs 2.80±0.68; 374 
P=0.04)(Fig. 5, panel A). Finally, treatment of 990G-CASR-HEK293 cells with 0.01 µM R568 375 
blunted the effect of FLNA loss as observed in 990R-CASR-expressing cells, though, in presence of 376 
FLNA, 990G-CASR-expressing cells showed higher [Ca
2+
]o-induced phospho-ERK levels than 377 
990R-CASR-expressing cells reaching statistically significance at 3.0 mM and 5.0 mM [Ca
2+
]o 378 
(3.10±0.34 vs 1.94±0.38 and 3.13±0.20 vs 2.48±0.03, respectively; P=0.04) (Fig. 5, panel B), in 379 
agreement with previous report (Terranegra et al. 2010).  380 
 381 
Discussion 382 
In the present study, the scaffold protein filamin A (FLNA) was firstly shown to be down-383 
regulated in human parathyroid tumors. Most cells in normal parathyroid glands expressed full-384 
length FLNA protein in cytoplasm and in association with membrane, while FLNA-expressing cells 385 
were variably reduced in parathyroid adenomas with tumor samples displaying an immunostaining 386 
pattern similar to that in normal glands and samples with a proportion of FLNA-expressing cells 387 
less than 10%. FLNA-expressing cells were definitely reduced in all the parathyroid carcinomas 388 
samples. Loss of FLNA expression has been reported in prolactin-secreting pituitary tumors 389 
(Peverelli et al. 2012), where it is related to dopamine-resistance, at variance with the increased 390 
expression detected in a variety of human cancers. The role of FLNA in tumorigenesis is complex 391 
and related to its subcellular localization: as scaffold protein, FLNA interacts with receptors 392 
localized in membranes; as cytoplasmic protein, FLNA functions in various growth signaling 393 
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pathways, such as vascular endothelial growth factor, R-Ras and integrin signaling; as nuclear 394 
active cleaved fragment, it interacts with transcription factors and nuclear receptors (Savoy & 395 
Ghosh 2013). In human parathyroid tumor cells, full-length FLNA was localized in membrane and 396 
in cytoplasm, similarly to what reported in bovine parathyroid cells (Hjälm et al. 2001); in addition, 397 
cleaved FLNA fragment could be detected in the nuclear protein fractions, suggesting FLNA 398 
potential involvement in multiple regulatory pathways in parathyroid tumor cells.  399 
Parathyroid tumors are characterized by extracellular calcium insensitivity (Corbetta et al. 400 
2000) and loss of CASR expression: compared with normal parathyroid glands, both CASR mRNA 401 
and protein are down-regulated in parathyroid adenomas (Kawata et al. 2006; Yano et al. 2003), 402 
carcinomas (Haven et al. 2004, Wittenveen et al. 2011) and primary and secondary hyperplasia 403 
(Martin-Salvago et al. 2003; Latus et al. 2013; Varshney et al. 2013a). CASR gene mutations have 404 
been rarely identified in sporadic parathyroid tumors (Frank-Raue et al. 2011; Guarnieri et al. 2010) 405 
and CASR gene deregulation is not sustained by promoter hypermethylation (Varshney et al. 406 
2013b). Therefore, alternative mechanisms might induce CASR mRNA and protein downregulation 407 
in parathyroid tumor cells. It has been reported in HEK293 cells stably transfected with CASR that 408 
FLNA interaction with CASR carboxyl terminal tail (Awata et al. 2001) is required for CASR 409 
stabilization through attenuation of its degradation (Zhang & Breitwieser 2005). We tested the 410 
hypothesis that down-regulation of CASR expression might be related to loss of FLNA in 411 
parathyroid tumors. We performed in vitro studies to investigate the effect of FLNA loss on CASR 412 
expression levels. Experiments were realized in HEK293 cells transiently transfected with 990R-413 
CASR because lack of suitable human parathyroid cells; a robust cell system has been developed, 414 
where unspecific effects of CASR plasmids and FLNA siRNA co-transfection were ruled out. Loss 415 
of FLNA significantly reduced the 990R-CASR expression levels both in the total protein pools and 416 
in the membrane protein fractions, suggesting an involvement of FLNA in stabilization of 990R-417 
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CASR proteins in HEK293 cells. Indeed, loss of FLNA reduced also CASR mRNA levels, 418 
suggesting that FLNA might be active on CASR gene regulation, likely at post-transcriptional level 419 
(Savoy et al. 2015). In parathyroid adenomas, FLNA gene expression levels positively correlated 420 
with CASR gene expression levels, suggesting a FLNA-mediated modulation of CASR gene 421 
transcription; this hypothesis is further supported by the detection in the parathyroid adenomas 422 
nuclear protein fractions of cleaved FLNA fragments accumulation, which has been demonstrated 423 
to directly regulate gene transcription (Savoy & Ghosh 2013). FLNA and/or CASR mRNA levels 424 
did not correlate with PHPT severity, suggesting that expression of these molecules is not a major 425 
determinant of the clinical phenotype associated with parathyroid tumors. Indeed, FLNA and CASR 426 
protein expression levels in parathyroid adenomas showed different patterns ranging from tumors 427 
with either low or high FLNA and CASR expression levels to tumors with discordant FLNA and 428 
CASR expression, in line with the wide range of reduced sensitivity to extracellular calcium 429 
characterizing the parathyroid tumors.     430 
We further tested the hypothesis that FLNA is involved in the regulation of the CASR-431 
mediated ERK activation and, firstly, evaluated the effect of the CASR agonist R568 when FLNA 432 
was reduced. FLNA interaction with CASR facilitates ERK phosphorylation (Zhang & Breitwieser 433 
2005) and CASR activation increases ERK phosphorylation in human normal and tumor 434 
parathyroid cells (Corbetta et al. 2002). In line with the previous report (Zhang & Breitwieser 435 
2005), in HEK293 cells transiently transfected with 990R-CASR, FLNA gene silencing reduced the 436 
[Ca
2+
]o-induced ERK phosphorylation. Treatment with R568 blunted the effect of FLNA loss, 437 
consistent with the stabilizing effect of R568 on CASR membrane expression demonstrated in 438 
previous study (Huang & Breitwieser 2007; Miedlich et al. 2004). 439 
FLNA interacts with the CASR carboxyl terminal tail at the domain between 972 and 997 440 
aminoacid residues (Awata et al. 2001; Hjalm et al. 2001). In this region, single nucleotide 441 
polymorphic variants have been identified and extensively investigated for the association with 442 
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phenotype (Cetani et al. 2002; Mingione et al. 2015; Vezzoli et al. 2015) and with the sensitivity to 443 
CASR agonist treatment in PHPT cohorts (Vezzoli et al. 2015). Just inside the FLNA binding 444 
region, a non-conservative CASR polymorphism, Arg990Gly (R990G) induces a gain of function in 445 
the receptor activity (Vezzoli et al. 2002; Scillitani et al. 2004; Corbetta et al. 2006). We 446 
investigated whether 990G allele affects the interaction of CASR C-terminus with FLNA testing the 447 
effect of FLNA loss on CASR-induced ERK phosphorylation in HEK293 cells transfected with 448 
990G-CASR. Similarly to what observed with 990R-CASR, FLNA loss reduced 990G-CASR 449 
mRNA in 990G-CASR transfected cells. Parathyroid tumors harboring the 990G-CASR variant do 450 
not show significant differences in FLNA and CASR mRNA expression levels compared with 451 
tumors harboring the more frequent 990R-CASR variant. Loss of FLNA also reduced 990G-CASR 452 
protein levels in both total and membrane protein fractions, though in presence of endogenous 453 
FLNA, expression of 990G-CASR in cell membrane was slightly higher than that of the 990R-454 
CASR. Moreover, analyzing the effect of FLNA loss on 990G-CASR- and 990R-CASR-induced 455 
ERK phosphorylation, three conditions characterized by increasing sensitivity of CASR-mediated 456 
ERK activation could be identified: the less sensitive condition was determined by loss of FLNA 457 
associated with the 990R allele, while the most sensitive condition was provided by co-expression 458 
of FLNA and 990G allele. The conditions characterized by loss of FLNA associated with the 990G 459 
allele, and conserved FLNA associated with the 990R allele, displayed a variable reduced 460 
sensitivity. Nonetheless, as observed with 990R-CASR, R568 treatment was efficient in rescuing 461 
990G-CASR sensitivity to [Ca
2+
]o in absence of FLNA.  462 
In conclusion, FLNA is variably down-regulated in parathyroid tumors both at mRNA and 463 
protein levels. Therefore, parathyroid tumor cells are characterized by receptor and post-receptor 464 
defects, namely loss of CASR (Martin-Salvago et al. 2003; Yano et al. 2003; Haven et al. 2004; 465 
Kawata et al. 2006; Wittenween et al. 2011; Latus et al. 2013; Varshney et al. 2013a), Gq/11 466 
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protein (Corbetta et al. 2000) and FLNA. Data about loss of FLNA in 990R-CASR-transfected 467 
HEK293 cells confirmed previously reported results: reduction of CASR protein and of CASR-468 
induced ERK phosphorylation. We further extended investigation to the FLNA effect on CASR 469 
mRNA expression, finding that it is affected and therefore suggesting an additional FLNA-related 470 
deregulation, also supported by cleaved FLNA nuclear localization. Though the 990G allele was 471 
associated with increased sensitivity to [Ca
2+
]o, FLNA is required for receptor protein expression 472 
and ERK signaling activation. Treatment with R568 agonist is effective in presence of different 473 
CASR and FLNA deregulated conditions. 474 
Admittedly, our conclusions were limited by the fact that functional experiments were 475 
performed in HEK293 cells and could not be replicated in human normal or tumor parathyroid cells. 476 
It should also be considered that FLNA has been reported to interact with over 90 proteins, which 477 
indicates the numerous pathways that FLNA can affect (Stossel et al. 2001). Therefore, in 478 
parathyroid tumors with loss of FLNA, intracellular pathways other than ERK signaling might be 479 
impaired and contribute to the tumor phenotype. 480 
 481 
List of abbreviations 482 
FLNA, filamin A 483 
CASR, calcium-sensing receptor 484 
PAds, parathyroid adenomas 485 
PCas, parathyroid carcinomas 486 
PaNs, normal parathyroid glands 487 
PHPT, primary hyperparathyroidism 488 
Page 20 of 39
  
 
Mingione et al. 21
ERK, extracellular-signal-regulated kinase 489 
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Legends 
Figure 1. Filamin A protein expression in human normal parathyroid glands and 
parathyroid tumors. A) Representative tissue sections analyzed by immunohistochemistry 
with specific anti-full-length FLNA antibody. a, intense staining in the cytoplasm and at 
membrane level in epithelial cells of normal parathyroid gland; white arrow indicates 
endothelial cells, considered as positive internal control; insert, magnification showing 
membrane and cytoplasmic specific staining for FLNA in a parathyroid cells (white head of 
arrow). b, proportion of FLNA-expressing cells (50%)  similar to normal glands in a sporadic 
PAds; insert, magnification showing FLNA-expressing cells (white head of arrow) besides 
negative or poor-expressing cells; white arrow indicates positivie endothelial cells. c, PAd 
section where FLNA staining involves only endothelial cells (white arrow). d, PCa section 
negative for FLNA specific immunostaining; white arrow indicates positivie endothelial 
cells. Scale bars represent 100 µm; a, b, c, and d, were imaged at 20X magnification; inserts 
were imaged at 40X magnification. B) Proportions of full-length FLNA-expressing cells 
detected by immunohistochemistry in normal parathyroid glands (PaNs), in parathyroid 
adenomas (PAds) and in parathyroid carcinomas (PCas); medians and interquartile ranges are 
shown. C) Confocal microscope immunofluorescent images of PAds-derived cultured single 
cells: a, Hoechst nuclear staining; b, FLNA-expressing (green) cells at membrane and 
cytoplasmic levels; c, CASR-expressing (red) cells; d, merged image showing that a small 
subset of cells co-expressing FLNA and CASR at high levels; inserts, magnification of the 
cell indicated by the white arrows. Scale bars represent 20 µm; a, b, c and d were imaged at 
100X magnification; inserts were imaged at 200X magnification. D) Immunoblot with a 
specific antibody against the 100 kDa calpain cleaved FLNA fragment (C-FLNA) on 
fractioned proteins from HEK293 cells and PAds; the antibody detects also  faint bands of 
270 kDa in the nuclear protein fractions corresponding to the full-length FLNA (F-FLNA); 
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histone H3 is used as control for the nuclear proteins; C, cytoplasmic; N, nuclear; HEK293, 
HEK293 cell preparation; PAd, parathyroid adenoma. 
 
Figure 2. Effects of FLNA silencing in CASR-transfected HEK293 cells. Mean expression 
levels quantified by densitometry of the indicated proteins in every cell preparations (left 
diagrams); representative western blot of the experiments (on the right). A) Endogenous 
FLNA silencing was efficient in HEK293 cells co-transfected with the empty vector, the 
990R-CASR and the 990G-CASR; the representative western blot shows the full-length 
FLNA protein of 280 kDa; GAPDH was used as internal control; B) Endogenous FLNA 
silencing induced a down-regulation of both 990R-CASR and 990G-CASR proteins in total 
protein extractions, while the FLNA control siRNA did not affect the CASR expression 
levels; the representative western blot shows the CASR monomeric isoforms of 140-160 kDa; 
β-actin was used as internal control; C) Endogenous FLNA silencing induced a down-
regulation of both 990R-CASR and 990G-CASR proteins in membrane protein fractions, 
while the FLNA control siRNA did not affect the CASR expression levels; the representative 
western blot shows the CASR monomeric isoforms of 140-160 kDa; Na/K-ATPase was used 
as internal control;. *, P<0.001; **, P<0.05; Ctrl siRNA, control FLNA siRNA. 
 
Figure 3. FLNA and CASR mRNA levels in CASR-transfected HEK-293 cells and 
sporadic parathyroid adenomas. A) Effect of FLNA silencing on CASR mRNA expression 
levels in 990R-CASR-HEK293 and 990G-CASR-HEK293 cells; columns represent means 
and SEMs; *, P<0.05. B) Tumor FLNA expression levels positively correlated with CASR 
expression levels in a series of 74 sporadic parathyroid adenomas; the best-fit line 
(continuous line) and 95% confidence bands (dashed lines) are shown. C) Boxes and 
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whiskers representing expression levels of FLNA in tumors harboring the 990R allele (990R-
CASR) compared with those detected in tumors harboring the 990G allele of the CASR gene 
(990G-CASR); horizontal line in the boxes represent the median values, whiskers represent 
minimum to maximum values, black dots represent single samples. D) Boxes and whiskers 
representing expression levels of CASR in tumors harboring the 990R allele (990R-CASR) 
compared with those detected in tumors harboring the 990G allele of the CASR gene (990G-
CASR); horizontal line in the boxes represented the median values, whiskers represented 
minimum to maximum values, black dots represent single sample. 
 
Figure 4. FLNA and CASR expression by western blot analysis in parathyroid 
adenomas. A) The three different bands corresponding to the monomeric immature 
glycosylated (140 kDa), the mature glycosylated (160 kDa) and the dimeric (280 kDa) forms 
of CASR were visualized; the band at 270 kDa corresponding to full-lenght FLNA was 
detected; actin was used as internal control; C+, HEK293 stably transfected with CASR; C-, 
HEK293 cells; K, human normal kidney; PAd, parathyroid adenoma; B) Lack of correlation 
between CASR and FLNA protein expression levels detected by western blot in parathyroid 
adenomas. The band intensities, corresponding to the levels of protein expression, were 
measured by Image J software.  
 
Figure 5. Effect of FLNA silencing in CASR-activated ERK signaling in CASR-
transfected HEK293 cells. A) In HEK293 cells transfected with the 990G-CASR and 
endogenous FLNA (black dashed line), 990G-CASR activation by increasing [Ca2+]o 
stimulated ERK phosphorylation at higher levels than that observed in 990R-CASR-
expressing cells (black continuous line), reaching the statistical significance at 5.0 mM 
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[Ca2+]o. Loss of FLNA by treatment with siRNA reduced 990G-CASR-induced phospho-
ERK levels (grey dashed line) with a significant difference at 5.0 mM [Ca2+]o. §§, Ctrl 
siRNA+990G-CASR vs Ctrl siRNA+990R-CASR, P=0.02; §, Ctrl siRNA+990G-CASR vs 
FLNA siRNA+990G-CASR, P=0.04; *, Ctrl siRNA+990R-CASR vs FLNA siRNA+990R-
CASR, P=0.02. B) Treatment of 990G-CASR-expressing HEK293 cells with increasing 
[Ca2+]o concentrations in presence of 0.01 µM R568 overrode the FLNA loss as observed in 
990R-CASR-expressing cells (grey continuous line), though, in presence of FLNA, 990G-
CASR-expressing cells (black dashed line) showed higher [Ca2+]o-induced phospho-ERK 
levels than 990R-CASR-expressing cells (black continuous line) reaching statistically 
significance at 5.0 mM [Ca2+]o. p44/42 ERK phosphorylation levels are reported on 
logarithmic scale; *, Ctrl siRNA+990G-CASR vs Ctrl siRNA+990R-CASR, P=0.02. 
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Table 1. Comparisons of biochemical parameters and tumor gene expressions between severe 
and mild PHPT patients. 
 Severe Mild 
No. patients 52 22 
Serum ionized calcium (mmol/l) a 1.57 (1.47-1.67) 1.46 (1.36-1.53) 
Serum alb-corr calcium (mg/dl) b 11.6 (11.0-12.3) 10.9 (10.7-11.2) 
Serum iPTH (pg/ml) 201.5 (130.0-319.0) 125.0 (104.0-254.4) 
Serum phosphate (mg/dl) 2.25 (1.88-2.6) 2.40 (2.13-2.73) 
Kidney stones (%) 41.7 0 
Osteoporosis (%) 70.8 0 
Mean Qty FLNA 0.07 (0.04-0.19) 0.08 (0.04-0.12) 
Mean Qty CASR 0.74 (0.41-1.08) 0.84 (0.48-1.46) 
 
alb-corr, albumin-corrected calcium (normal value: 8.2-10.4 mg/dl); iPTH, intact parathormone, 
Qty, gene expression relative quantity; FLNA, filamin A; CASR, calcium sensing receptor. a, 
P=0.0046; b, P=0.0003. Criteria for PHPT severity are according Marcocci et al. 2015.  
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